JPMorgan Chase & Co. downgraded Novavax, Inc. (NASDAQ:NVAX) to Neutral in a statement released earlier today.
- Updated: September 15, 2016
JPMorgan Chase & Co. has downgraded Novavax, Inc.(NASDAQ:NVAX) to Neutral in a report released on 9/16/2016.
Previously on Tuesday August 23 2016, Vetr Inc. released a statement on Novavax, Inc.(NASDAQ:NVAX) bumped the target price from $0.00 to $8.66 that indicated a possible upside of 0.17%.
Having a price of $8.34, Novavax, Inc. (NASDAQ:NVAX) traded 0.36% higher on the day. With the last stock close up 33.70% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. The company has registered a 50-day moving average of $7.35 and two hundred day average of $6.24. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares.
Novavax, Inc. has a one-year low of $4.08 and a 52 week high of $10.70. Novavax, Inc.’s market capitalization is presently $0.0.
In addition to JPMorgan Chase & Co. reporting it’s price target, a total of 8 equity analysts have released a ratings update on Novavax, Inc.. The 12-month target is $15.39 with five firms rating the company a strong buy, three firms rating the company a buy, 0 firms rating the stock a hold, 0 rating the company to underperform, and lastly 0 analystsrating the stock as sell.
Brief Synopsis About Novavax, Inc. (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.